Charles River Laboratories International 

$187.72
91
+$0.21+0.11% Today

Statistics

Day High
190.79
Day Low
185.16
52W High
226.77
52W Low
145.05
Volume
493,900
Avg. Volume
-
Mkt Cap
9.24B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
1.94
2.34
2.73
3.12
Expected EPS
2.73186
Actual EPS
N/A

Financials

-3.59%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
8.03BRevenue
-288.68MNet Income

Analyst Ratings

208.63Average Price Target
The highest estimate is 265.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
63%
Hold
38%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRL. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Show more...
CEO
Ms. Birgit Girshick
Employees
18700
Country
United States
ISIN
US1598641074

Listings

0 Comments

Share your thoughts

FAQ

What is Charles River Laboratories International stock price today?
The current price of CRL is $187.72 USD — it has increased by +0.11% in the past 24 hours. Watch Charles River Laboratories International stock price performance more closely on the chart.
What is Charles River Laboratories International stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Charles River Laboratories International stocks are traded under the ticker CRL.
Is Charles River Laboratories International stock price growing?
CRL stock has risen by +0.69% compared to the previous week, the month change is a +24.44% rise, over the last year Charles River Laboratories International has showed a +25.61% increase.
What is Charles River Laboratories International market cap?
Today Charles River Laboratories International has the market capitalization of 9.24B
When is the next Charles River Laboratories International earnings date?
Charles River Laboratories International is going to release the next earnings report on August 12, 2026.
What were Charles River Laboratories International earnings last quarter?
CRL earnings for the last quarter are 2.06 USD per share, whereas the estimation was 1.94 USD resulting in a +5.99% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Charles River Laboratories International revenue for the last year?
Charles River Laboratories International revenue for the last year amounts to 8.03B USD.
What is Charles River Laboratories International net income for the last year?
CRL net income for the last year is -288.68M USD.
How many employees does Charles River Laboratories International have?
As of June 15, 2026, the company has 18,700 employees.
In which sector is Charles River Laboratories International located?
Charles River Laboratories International operates in the Health & Wellness sector.
When did Charles River Laboratories International complete a stock split?
Charles River Laboratories International has not had any recent stock splits.
Where is Charles River Laboratories International headquartered?
Charles River Laboratories International is headquartered in Wilmington, United States.